Idhifa (Enasidenib) is specifically approved by the U.S. Food and Drug Administration (FDA) to treat relapsed or refractory acute myeloid leukemia (AML) that has tested positive for a mutation in the isocitrate dehydrogenase-2 (IDH2) gene. There is no information in my knowledge base indicating that Idhifa is used for Show Full Answer

Idhifa (Enasidenib) is specifically approved by the U.S. Food and Drug Administration (FDA) to treat relapsed or refractory acute myeloid leukemia (AML) that has tested positive for a mutation in the isocitrate dehydrogenase-2 (IDH2) gene. There is no information in my knowledge base indicating that Idhifa is used for myelodysplastic syndromes (MDS).

 This AI-generated response comes from MyLeukemiaTeam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

Treatment Advances for MDS | MyLeukemiaTeam

Idhifa (Enasidenib) for Leukemia | MyLeukemiaTeam